Editorial: Biologics for inflammatory bowel diseases in the Asia-Pacific: Can we afford to use them, can we afford not to?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 7, 2009, Pages 1160-1162

  Gearry, Richard B ^a   Irving, Peter M ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; NARCOTIC ANALGESIC AGENT; PREDNISONE; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ASIA; COST OF ILLNESS; CROHN DISEASE; DIAGNOSTIC ERROR; DRUG COST; DRUG SAFETY; EDITORIAL; ENTERITIS; FECES ANALYSIS; GENE MUTATION; HEALTH CARE COST; HEREDITY; HUMAN; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFECTIOUS DIARRHEA; PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REGISTER; REMISSION; RISK FACTOR; TUBERCULOSIS; ULCERATIVE COLITIS; AUSTRALIA; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; ETHNOLOGY; HEALTH CARE DELIVERY; HOSPITALIZATION; NOTE; PATIENT SELECTION; TIME; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASIA; AUSTRALIA; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GASTROINTESTINAL AGENTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; PATIENT SELECTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 68749090131     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05896.x     Document Type: Editorial

References (19)

1. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract. Res. Clin. Gastroenterol. 2004 18 : 463 79.
2. Gearry RB, Richardson A, Frampton CM et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm. Bowel Dis. 2006 12 : 936 43.
3. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm. Bowel Dis. 2004 10 : 646 51.
4. Thia KT, Loftus EV Jr., Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J. Gastroenterol. 2008 103 : 3167 82.
5. Ouyang Q, Tandon R, Goh KL et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J. Gastroenterol. Hepatol. 2006 21 : 1772 82.
6. Irving PM, Gibson PR. Infections and IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008 5 : 18 27.
7. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007 133 : 1779 86.
8. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006 4 : 621 30.
9. Fidder HH, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2008 58 (4 501 8.
10. World Health Organisation. Global tuberculosis control - surveillance, planning and financing. WHO report, 2008. World Health Organisation, 2008.
11. Periodic safety update reports (PSUR 16, October, 2007; PSUR 17, April 2008).
12. Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2007 22 : 1671 7.
13. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 9.
14. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. 1997 337 : 1029 35.
15. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
16. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 33. quiz 591.
17. Access Economics. The economic costs of Crohn's disease and ulcerative colitis, 9 June, 2007 (commissioned by the Australian Crohn's and Colitis Association).
18. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol. 2004 99 : 91 6.
19. Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment. Pharmacol. Ther. 2007 26 : 313 29.